SCHOTT Pharma AG & Co. KGaA

BRIEF

published on 04/30/2024 at 17:05, 6 months 21 days ago

SCHOTT Pharma Names Tobias Erfurth as New Head of Investor Relations

Pharmaceutical Industry Investor Relations SCHOTT Pharma Financial Profile Tobias Erfurth
PRESS RELEASE

published on 04/30/2024 at 17:00, 6 months 21 days ago

SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations
SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations effective August 2024. With his extensive experience in finance and capital markets, Erfurth aims to enhance SCHOTT Pharma's presence in the capital markets

Investor Relations Capital Markets SCHOTT Pharma Finance Tobias Erfurth
BRIEF

published on 03/18/2024 at 18:45, 8 months 2 days ago

SCHOTT Pharma Announces Major Expansion in the U.S. with a New Syringe Manufacturing Facility

North Carolina SCHOTT Pharma Manufacturing Expansion Prefillable Syringes Pharmaceutical Supply Chain
PRESS RELEASE

published on 03/18/2024 at 18:40, 8 months 2 days ago

SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility
SCHOTT Pharma AG & Co. KGaA announces expansion in the U.S. with new prefilled syringe manufacturing facility in Wilson, North Carolina. $371 million investment to add over 400 jobs

Expansion North Carolina SCHOTT Pharma Manufacturing Facility Prefillable Syringe
BRIEF

published on 03/14/2024 at 16:31, 8 months 7 days ago

Shareholders Unanimously Approve Agenda at SCHOTT Pharma's Inaugural AGM

Annual General Meeting Dividend Pharmaceutical Packaging SCHOTT Pharma SDAX
PRESS RELEASE

published on 03/14/2024 at 16:26, 8 months 7 days ago

Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda
SCHOTT Pharma's 2024 AGM sees shareholders approving all agenda items. The company continues on its profitable growth path, focusing on high-value solutions for pharmaceutical trends

Annual General Meeting Shareholders SCHOTT Pharma High-value Solutions Pharmaceutical Trends
PRESS RELEASE

published on 02/29/2024 at 07:00, 8 months 21 days ago

SCHOTT Pharma reports good start into fiscal year 2024
SCHOTT Pharma reports good start into fiscal year 2024 with Q1 revenues of EUR 232m, marking an 8% increase yoy at constant currencies. EBITDA margin at 27.9%. Guidance confirmed

Revenues EBITDA Margin SCHOTT Pharma Guidance Q1 2024
BRIEF

published on 02/29/2024 at 07:00, 8 months 21 days ago

SCHOTT Pharma has a good start to fiscal year 2024 with sustained growth

Innovation Revenue Growth SCHOTT Pharma Quarterly Results High Added Value Solutions
PRESS RELEASE

published on 01/26/2024 at 07:00, 9 months 26 days ago

SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory
SCHOTT Pharma AG & Co. KGaA delivers on 2023 targets with 9% revenue growth to EUR 899m and maintains high EBITDA margin of 26.6%. Strategic shift towards high-value solutions accelerates with strong profitability.

Revenue Growth EBITDA Margin SCHOTT Pharma Annual Report Forecast
PRESS RELEASE

published on 10/06/2023 at 18:10, 1 year 1 month ago

SCHOTT Pharma IPO: Early termination of stabilization period and full exercise of the Greenshoe Option

Published on 11/21/2024 at 17:35, 22 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 27 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 1 hour 27 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 1 hour 56 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 1 hour 57 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 1 hour 57 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 2 hours 15 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 2 hours 33 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 2 hours 34 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 2 hours 35 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 10 hours 59 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 22 hours 37 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 10 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE

News